Geron Corp (GERN)

$1.28 +0.04 (3.23%)
Market Cap 791.14M
Revenue (ttm) 76.99M
Net Income (ttm) -174.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.74%
Debt to Equity Ratio 0.46
Volume 5,449,900
Avg Vol 7,119,112
Day's Range N/A - N/A
Shares Out 638.02M
Stochastic %K 42%
Beta 0.57
Analysts Sell
Price Target $3.86

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 473 7700
Address:
919 East Hillsdale Boulevard, Suite 250, Foster City, United States
ZoeyTanner
ZoeyTanner Oct. 27 at 6:35 PM
$GERN Up a penny, down a penny. The legacy for Harout Semerjian? At least, we will have a live ceo in 8 business days to explain why we are 0ne hundred twenty pennies a share after three decades. Nothing at ASH or ASCO ? Does not bode well for SH.
0 · Reply
patso1964
patso1964 Oct. 27 at 4:15 PM
$GERN https://ir.geron.com/investors/events/Events/event-details/2025/Q3-2025-Geron-Earnings-Conference-Call-2025-3fGIR6tzU5/default.aspx
0 · Reply
t2026
t2026 Oct. 27 at 6:26 AM
$GERN I’m starting a position. 12500 shares and counting. In the NCCN guidelines, hematologists are becoming aware this is by no means a perfect drug but it’s something that many low risk MDS patients will see and expanded uses possibly in MF. Cash runway into 2027 this is a worth the gamble
1 · Reply
ZoeyTanner
ZoeyTanner Oct. 26 at 5:43 PM
$GERN
1 · Reply
ZoeyTanner
ZoeyTanner Oct. 26 at 5:38 PM
$GERN this thing really is a 'crying shame', if held for the year down 75%, and much more the longer you've held. ALL happening, while the bull markets has blown out all highs
0 · Reply
stanky_dank27
stanky_dank27 Oct. 25 at 4:45 PM
$GERN imetelstat being mentioned as part of an expanding landscape of pre allogenic stem cell transplant treatments in MF. (Link to X post at end) What’s interesting to me is the IMproveMF trial is in combination with 4 of these. IMproveMF trial is currently testing the safety profile and efficacy of imetelstat with 4 of these listed treatments. Additionally, I believe, Geron holds the patent for imetelstat + BCL2 inhibitors for treatment of hematological cancers, which is also listed. There needs to be an early stage trial for safety and efficacy with some BCL2 inhibitors getting in motion. I see an early NDA submission after IMpactMF interim data comes out at the 35% event mark. With an approval here, and positive data in safety and efficacy of combinations, a bidding war will ensue for Geron between some JAKi and BCL2 powerhouses. Imetelstat has the potential to be combined with half the treatment landscape. https://x.com/ahmedko45911157/status/1981968029836575209?s=46
1 · Reply
Huntlardo24
Huntlardo24 Oct. 25 at 12:14 PM
$GERN I see why the person bought November 1.5$ contracts we just had the 12 EMA crossing over the SMA on the monthly time frame. A lagging bullish indicator of trend shifting. almost time too boogie, hold onto your butts.
0 · Reply
Tacto
Tacto Oct. 25 at 2:07 AM
$GERN Here's a picture from the Nasdaq website showing the 6.2 million share transaction at 4:04pm, and the total for the day of 11.6 million shares transacted, which takes into account regular hours and all of after-hours https://www.nasdaq.com/market-activity/stocks/gern .
0 · Reply
Tacto
Tacto Oct. 25 at 1:57 AM
$GERN Why does Nasdaq show a transaction for 6,217,006 shares at $1.24 at 4:04pm? Taking into account regular hours and after-hours they show total volume of 11,634,899 Maybe one institution transferring to another, or from one of their accounts to another of their accounts? Had to have been done in the dark (off-exchange), for 6 million shares not to move the needle, that's for sure..
2 · Reply
ZdP2
ZdP2 Oct. 24 at 9:06 PM
$GERN Only been here a month or so, so I can still handle the pain 😅
0 · Reply
Latest News on GERN
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 27, 2025, 8:00 AM EDT - 13 hours ago

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy

Oct 23, 2025, 10:02 AM EDT - 4 days ago

Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 20, 2025, 5:32 PM EDT - 7 days ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Announces Executive Leadership Transitions and Appointments

Oct 13, 2025, 4:34 PM EDT - 14 days ago

Geron Corporation Announces Executive Leadership Transitions and Appointments

Making Money In Biotech Stocks

Oct 9, 2025, 5:00 PM EDT - 18 days ago

Making Money In Biotech Stocks

SNDX

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Aug 14, 2025, 5:23 PM EDT - 2 months ago

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2025, 4:01 PM EDT - 2 months ago

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron: I Think We've Seen This Movie Before

Aug 8, 2025, 9:30 AM EDT - 2 months ago

Geron: I Think We've Seen This Movie Before

Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:01 PM EDT - 2 months ago

Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 7:01 AM EDT - 2 months ago

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Jul 28, 2025, 8:00 AM EDT - 3 months ago

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Conservative Vision Of A Positive Future For Geron

Jun 3, 2025, 9:57 AM EDT - 5 months ago

Conservative Vision Of A Positive Future For Geron

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 28, 2025, 8:30 AM EDT - 5 months ago

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

May 9, 2025, 8:28 AM EDT - 6 months ago

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

May 8, 2025, 11:24 PM EDT - 6 months ago

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:50 PM EDT - 6 months ago

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

May 7, 2025, 12:33 PM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 6 months ago

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 24, 2025, 9:33 PM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 18, 2025, 4:30 PM EDT - 6 months ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 9, 2025, 10:40 AM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Mar 31, 2025, 4:32 PM EDT - 7 months ago

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 4:30 PM EDT - 7 months ago

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 7 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS LLY NVO SEPN

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

Mar 22, 2025, 12:31 PM EDT - 7 months ago

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

TBBK

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Mar 17, 2025, 5:19 PM EDT - 8 months ago

Geron Corp: How Concerned Should We Be About Rytelo Sales?

ZoeyTanner
ZoeyTanner Oct. 27 at 6:35 PM
$GERN Up a penny, down a penny. The legacy for Harout Semerjian? At least, we will have a live ceo in 8 business days to explain why we are 0ne hundred twenty pennies a share after three decades. Nothing at ASH or ASCO ? Does not bode well for SH.
0 · Reply
patso1964
patso1964 Oct. 27 at 4:15 PM
$GERN https://ir.geron.com/investors/events/Events/event-details/2025/Q3-2025-Geron-Earnings-Conference-Call-2025-3fGIR6tzU5/default.aspx
0 · Reply
t2026
t2026 Oct. 27 at 6:26 AM
$GERN I’m starting a position. 12500 shares and counting. In the NCCN guidelines, hematologists are becoming aware this is by no means a perfect drug but it’s something that many low risk MDS patients will see and expanded uses possibly in MF. Cash runway into 2027 this is a worth the gamble
1 · Reply
ZoeyTanner
ZoeyTanner Oct. 26 at 5:43 PM
$GERN
1 · Reply
ZoeyTanner
ZoeyTanner Oct. 26 at 5:38 PM
$GERN this thing really is a 'crying shame', if held for the year down 75%, and much more the longer you've held. ALL happening, while the bull markets has blown out all highs
0 · Reply
stanky_dank27
stanky_dank27 Oct. 25 at 4:45 PM
$GERN imetelstat being mentioned as part of an expanding landscape of pre allogenic stem cell transplant treatments in MF. (Link to X post at end) What’s interesting to me is the IMproveMF trial is in combination with 4 of these. IMproveMF trial is currently testing the safety profile and efficacy of imetelstat with 4 of these listed treatments. Additionally, I believe, Geron holds the patent for imetelstat + BCL2 inhibitors for treatment of hematological cancers, which is also listed. There needs to be an early stage trial for safety and efficacy with some BCL2 inhibitors getting in motion. I see an early NDA submission after IMpactMF interim data comes out at the 35% event mark. With an approval here, and positive data in safety and efficacy of combinations, a bidding war will ensue for Geron between some JAKi and BCL2 powerhouses. Imetelstat has the potential to be combined with half the treatment landscape. https://x.com/ahmedko45911157/status/1981968029836575209?s=46
1 · Reply
Huntlardo24
Huntlardo24 Oct. 25 at 12:14 PM
$GERN I see why the person bought November 1.5$ contracts we just had the 12 EMA crossing over the SMA on the monthly time frame. A lagging bullish indicator of trend shifting. almost time too boogie, hold onto your butts.
0 · Reply
Tacto
Tacto Oct. 25 at 2:07 AM
$GERN Here's a picture from the Nasdaq website showing the 6.2 million share transaction at 4:04pm, and the total for the day of 11.6 million shares transacted, which takes into account regular hours and all of after-hours https://www.nasdaq.com/market-activity/stocks/gern .
0 · Reply
Tacto
Tacto Oct. 25 at 1:57 AM
$GERN Why does Nasdaq show a transaction for 6,217,006 shares at $1.24 at 4:04pm? Taking into account regular hours and after-hours they show total volume of 11,634,899 Maybe one institution transferring to another, or from one of their accounts to another of their accounts? Had to have been done in the dark (off-exchange), for 6 million shares not to move the needle, that's for sure..
2 · Reply
ZdP2
ZdP2 Oct. 24 at 9:06 PM
$GERN Only been here a month or so, so I can still handle the pain 😅
0 · Reply
viking1111
viking1111 Oct. 24 at 6:56 PM
$GERN too much slippage. A yr and a half of downtrend and sideways trading. Maybe once all the selling stops.
0 · Reply
TrailBlazer7
TrailBlazer7 Oct. 24 at 5:50 PM
$GERN we still don't have clarity on what has happened to Dr. Faye Feller. While some have posted on other BBs that her title has been changed to Chief Development Officer, I have not found anything to verify this and she has been removed from the Geron webpage. More concerning, yesterday's presentation that Dr. Feller was supposed to give at the Global MPN Scientific Foundation titled "What is Imetelstat" was replaced by a presentation titled "Introduction to Geron" given by Christian Dimaano, Vice President and Head of Medical Affairs. This new leadership needs to provide some transparency if Dr. Feller has been let go or resigned. They need to provide a very good explanation on why one of Geron's most qualified and articulate directors was let go. We deserve answers from Harout. I can understand cutting deadwood in the light of disappointing sales, but Dr. Feller was not involved in sales and she is anything BUT deadwood.
2 · Reply
Find_the_Cure
Find_the_Cure Oct. 24 at 5:06 PM
$GERN what’s the problem with this stock???
0 · Reply
Kosmokrat
Kosmokrat Oct. 24 at 3:31 PM
$GERN On Dec-6, 2023 Geron announced the 50% enrollment in their IMpactMF phase 3 trial, and they expected an interim analysis to be published mid-2025. This did not happen. Any idea why? Or any hint how the study is progressing? And when any results will be published?
1 · Reply
Huntlardo24
Huntlardo24 Oct. 24 at 2:06 PM
$GERN Options Alert: Nov. 21, 2025 Calls Option Chain Strike= $1.50; Ask= $.10; Vol= 2,452; OI= 1
0 · Reply
Tacto
Tacto Oct. 24 at 12:19 PM
$GERN Current view of EDGX
1 · Reply
Tacto
Tacto Oct. 24 at 12:17 PM
$GERN Here's a look at EDGX right now
0 · Reply
ZoeyTanner
ZoeyTanner Oct. 24 at 11:12 AM
$GERN If you are still here, I feel your pain. This is, and has been, the worst money grab of all biotech land.
0 · Reply
Bobfree
Bobfree Oct. 23 at 9:18 PM
$GERN
0 · Reply
lucgallo
lucgallo Oct. 23 at 5:37 PM
$GERN FWIW https://seekingalpha.com/article/4832400-geron-corporation-early-momentum-strong-leadership-plus-clear-path-to-growth-why-i-buy?mailingid=42145830&messageid=2800&position=rta_analysis_popular_main_0_title&serial=42145830.88&source=email_2800&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=42145830.88
0 · Reply
viking1111
viking1111 Oct. 23 at 2:19 PM
$GERN its good to look back 6 months to a yr on a chart, then go back a few more yrs. I looked back 3 yrs this am. There is more selling holding this down than just the high short int. Could be a past filing of a shelf/atm whatever it is I doubt its just the shorting holding this down so low. I mean the float didn't get as high as it is without a ton of dilution along the way.
1 · Reply
Dingo2
Dingo2 Oct. 23 at 2:17 PM
$GERN maybe GERN can get out of the churn soon like $NMRA
0 · Reply